See inside the Gatehouse BioHub: No other labs in all of BioPharma are as deeply integrated

[vc_row][vc_column][vc_column_text]Integration between biotech and Big Pharma has never before looked like this.[/vc_column_text][vc_single_image image=”1033″ img_size=”full” alignment=”center” onclick=”link_image”][vc_column_text]Both Astra Zeneca and Morphic Therapeutic decided to forego an originally planned divider wall. As far as we know, this creates the 1st completely integrated labs between Big Pharma and Biotech leading to valued personal interaction; and sharing of ideas, equipment, and resources.[/vc_column_text][vc_row_inner][vc_column_inner width=”1/2″][vc_column_text]

The Gatehouse BioHub

Credit entirely belongs to Astra Zeneca (AZ) for a vision of unprecedented collaboration and interaction.

Built by AZ in 2000, three buildings nestled quietly in the scenic woods of Waltham, Massachusetts comprise a vibrant research community for scientists from Astra Zeneca, Morphic Therapeutic, Corvidia, Entasis, Persomics, QIAGEN, and Xtuit.[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/2″][vc_single_image image=”1035″ img_size=”full” alignment=”center” onclick=”link_image” css=”.vc_custom_1485379997113{margin-top: 25px !important;}”][/vc_column_inner][/vc_row_inner][vc_column_text]At 382,000 square feet, the BioHub is absolutely massive and loaded with prime laboratory space and high-tech details.

Pooled Resources for Industry wide Interdisciplinary Technical Lectures.

BioHub members waiting to hear a  Scientific Talk from an academic expert.  The BioHub has a 150 seat auditorium with state of the art audio / video equipment.[/vc_column_text][vc_single_image image=”1037″ img_size=”full” alignment=”center” onclick=”link_image”][vc_column_text]

BioHub Christmas Party 2016.

[/vc_column_text][vc_single_image image=”1034″ img_size=”full” alignment=”center” onclick=”link_image”][vc_column_text]Astra Zeneca knows how to celebrate a productive year – 4 chefs; dozens of themed food items spread across the expansive work areas.[/vc_column_text][/vc_column][/vc_row]

Scroll to Top

Contact Us

TL1A and IL-23

Morphic is leveraging its structural biology expertise and medicinal chemistry capabilities to develop small molecule therapeutic candidates against non-integrin targets including TL1-A and IL-23. Inhibition of these pathways have potential as treatments for IBD through monotherapy and possibly in combination with other IBD treatment mechanisms including α4β7 inhibition.

α5β1

Morphic is developing small molecule inhibitors of the integrin α5β1 based on research demonstrating that fibronectin integrin inhibition suppresses pulmonary arterial smooth muscle cell proliferation. Potential indications include severe pulmonary hypertensive disease including pulmonary arterial hypertension.

Integrin Partnership: Janssen

Morphic entered a research partnership with Janssen in 2019 to discover inhibitors of undisclosed integrin targets. In 2021, this partnership was expanded to include an antibody activator of an integrin target, extending the application of Morphic’s knowledge of integrin biology into modalities beyond small molecules. The antibody activator program is the focus of our collaboration with Janssen today.

Undisclosed Targets

Morphic is leveraging the MInT Platform to discover therapeutically relevant small molecule inhibitors of targets across the integrin family to treat autoimmune diseases, cancer and fibrotic diseases.

Undisclosed Target for Pulmonary Arterial Hypertension

Morphic is deploying the MInT Platform to create small molecule inhibitors of an undisclosed integrin target for evaluation as a potential treatment for pulmonary arterial hypertension (PAH). PAH is a devastating, usually fatal disease characterized by elevated mean pressures in the pulmonary artery and associated with lung and heart dysfunction. Morphic’s PAH program is in preclinical development.

αvβ8 (MORF-088)

Morphic is developing small molecule inhibitors of the integrin αvβ8 for potential uses in myelofibrosis and a combination immuno-oncology approach for the treatment of solid tumors. αvβ8 is known to activate selective isoforms of TGF-β and Morphic has demonstrated that αvβ8 inhibition can drive increased platelet production and potentiate immune checkpoint blockade and potentially drive responses in checkpoint refractory tumors. Morphic’s αvβ8 inhibitors are in preclinical development.

Next Gen α4β7 Inhibitors

Morphic is developing a family of next generation α4β7 small molecule inhibitors with enhanced attributes using the MInT Platform. These candidates have distinct chemical properties from our first-generation inhibitors with differentiated selectivity, potency, and pharmacokinetic profiles. Morphic’s next generation α4β7 inhibitors are currently in preclinical development.